492 related articles for article (PubMed ID: 17389185)
21. Precursors of endometrial clear cell carcinoma.
Fadare O; Liang SX; Ulukus EC; Chambers SK; Zheng W
Am J Surg Pathol; 2006 Dec; 30(12):1519-30. PubMed ID: 17122507
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
23. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
25. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
26. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.
Caduff RF; Johnston CM; Svoboda-Newman SM; Poy EL; Merajver SD; Frank TS
Am J Pathol; 1996 May; 148(5):1671-8. PubMed ID: 8623934
[TBL] [Abstract][Full Text] [Related]
28. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
29. Histopathology of functional and neoplastic changes in cervix and endometrium.
Dallenbach-Hellweg G
Verh Dtsch Ges Pathol; 1997; 81():240-4. PubMed ID: 9474876
[TBL] [Abstract][Full Text] [Related]
30. A proposed model for endometrial serous carcinogenesis.
Zheng W; Xiang L; Fadare O; Kong B
Am J Surg Pathol; 2011 Jan; 35(1):e1-e14. PubMed ID: 21164282
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
32. Endometrial carcinoma: pathology and genetics.
Prat J; Gallardo A; Cuatrecasas M; Catasús L
Pathology; 2007 Feb; 39(1):72-87. PubMed ID: 17365824
[TBL] [Abstract][Full Text] [Related]
33. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
35. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
36. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
37. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
39. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas.
Katabuchi H; van Rees B; Lambers AR; Ronnett BM; Blazes MS; Leach FS; Cho KR; Hedrick L
Cancer Res; 1995 Dec; 55(23):5556-60. PubMed ID: 7585634
[TBL] [Abstract][Full Text] [Related]
40. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
Lax SF
Virchows Arch; 2004 Mar; 444(3):213-23. PubMed ID: 14747944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]